The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma
We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD
regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment.
After achievement of response, patients either underwent hematopoietic stem cell
transplantation (HSCT) or consolidation with hyper-CVAD.
Observational
Time Perspective: Retrospective
Overall survival
3-year
No
Korea: Institutional Review Board
LBL-CISL-1
NCT01813344
January 2012
Name | Location |
---|